NASDAQ
Bagsværd, Denmark and South San Francisco, CA, US, 9 December 2025 – Novo Nordisk and Akero Therapeutics Inc. (“Akero”) (Nasdaq: AKRO) today announced that Novo Nordisk's acquisition of Akero, announced on 9 October 2025, has been completed. With the...
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akero Therapeutics, Inc. (NasdaqGS: AKRO) to Novo ...
PHILADELPHIA , Nov. 12, 2025 /PRNewswire/ -- Berger Montague PC advises shareholders of Akero Therapeutics, Inc. ("Akero" or the "Company") about an investigation into the Company and members of its Board of Directors for potential breaches of fidu...
Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 96-week Phase 2b SYMMETRY trial and indicate potential to reduce risk of disease progression in compensated cirrhosis (F4c) due to MASH...
PHILADELPHIA , Nov. 4, 2025 /PRNewswire/ -- Berger Montague PC advises shareholders of Akero Therapeutics, Inc. ("Akero" or the "Company") about an investigation into the Company and members of its Board of Directors for potential breaches of fiduc...
PHILADELPHIA , Oct. 29, 2025 /PRNewswire/ -- Berger Montague PC advises shareholders of Akero Therapeutics, Inc. ("Akero" or the "Company") about an investigation into the Company and members of its Board of Directors for potential breaches of fiduc...
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akero Therapeutics, Inc. (NasdaqGS: AKRO) to Novo Nordi...
NEW YORK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Sec...
MILWAUKEE , Oct. 9, 2025 /PRNewswire/ -- The Ademi Firm is investigating Akero (NASDAQ: AKRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Novo Nordisk. Click here to learn how to join our investigation ...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Akero Therapeutics, Inc. (NASDAQ: AKRO) to Novo Nordisk A/S is fair to Akero shareholders. Under the terms of the proposed transaction, Ake...
No price data available for this timeframe.